Excellthera

Excellthera company information, Employees & Contact Information

Explore related pages

Excellthera email format Excellthera management contacts

Related company profiles:

ExCellThera is a world leader in enhanced blood stem cell therapies.

Company Details

Employees
19
Founded
-
Address
2950 Chemin De Polytechnique, Montreal,quebec,canada
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
excellthera.com
Keywords
blood stem cell expansion, bioengineering, immune cells, health care, gene therapy, cell engineering, HSCT, HSC, cell therapy, blood cancer, leukemia, AML, MDS, biotech, biotechnology, cord blood, bone marrow, peripheral blood, transplant, stem cells.
HQ
Montreal, Quebec
Competitors
Neurona Therapeutics, CCRM, OmniaBio, adMare BioInnovations, Notch Therapeutics, Senti Biosciences, Marker Therapeutics, Inc., Morphocell Technologies, CellCAN, C3i.
Looking for a particular Excellthera employee's phone or email?

Excellthera Questions

News

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells - PR Newswire Canada

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells PR Newswire Canada

ExCellThera’s first-in-class UM171 cell therapy is now approved in Europe - Labiotech.eu

ExCellThera’s first-in-class UM171 cell therapy is now approved in Europe Labiotech.eu

ExCellThera's novel blood cancer stem cell therapy Zemcelpro earns EU nod - Fierce Pharma

ExCellThera's novel blood cancer stem cell therapy Zemcelpro earns EU nod Fierce Pharma

ExCellThera Announces EMA’s Acceptance under Accelerated Assessment of Market Authorisation Application (MAA) for UM171 Cell Therapy for Patients with Hematological Malignancies who Lack a Readily Available Suitable Donor - GlobeNewswire

ExCellThera Announces EMA’s Acceptance under Accelerated Assessment of Market Authorisation Application (MAA) for UM171 Cell Therapy for Patients with Hematological Malignancies who Lack a Readily Available Suitable Donor GlobeNewswire

ExCellThera Announces Positive Phase 2 Study Results from UM171 Cell Therapy in Patients with High-risk Leukemias and Myelodysplasias at American Society of Hematology (ASH) 2023 Annual Meeting - Yahoo Finance

ExCellThera Announces Positive Phase 2 Study Results from UM171 Cell Therapy in Patients with High-risk Leukemias and Myelodysplasias at American Society of Hematology (ASH) 2023 Annual Meeting Yahoo Finance

Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells - PR Newswire

Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells PR Newswire

ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center - BioInformant

ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center BioInformant

Europe's CHMP gives thumbs up to ExCellThera's blood cancer cell therapy Zemcelpro - Fierce Pharma

Europe's CHMP gives thumbs up to ExCellThera's blood cancer cell therapy Zemcelpro Fierce Pharma

ExCellThera and Astellas enter into a license for the use of molecule UM171 in the field of pluripotent stem cells - GlobeNewswire

ExCellThera and Astellas enter into a license for the use of molecule UM171 in the field of pluripotent stem cells GlobeNewswire

Blood cancers: New generation stem cell transplant significantly reduces complications for patients - EurekAlert!

Blood cancers: New generation stem cell transplant significantly reduces complications for patients EurekAlert!

ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation - GlobeNewswire

ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation GlobeNewswire

ExCellThera announces settlement of its patent infringement claims against Selleck Chemicals - GlobeNewswire

ExCellThera announces settlement of its patent infringement claims against Selleck Chemicals GlobeNewswire

Companies like Excellthera

CellCAN logo - Similar company to Excellthera

Cellcan

6
Notch Therapeutics logo - Similar company to Excellthera

Notch Therapeutics

24
Morphocell Technologies logo - Similar company to Excellthera

Morphocell Technologies

33
Neurona Therapeutics logo - Similar company to Excellthera

Neurona Therapeutics

97
OmniaBio logo - Similar company to Excellthera

Omniabio

162
adMare BioInnovations logo - Similar company to Excellthera

Admare Bioinnovations

71
Marker Therapeutics, Inc. logo - Similar company to Excellthera

Marker Therapeutics,...

27
CCRM logo - Similar company to Excellthera

Ccrm

225
Senti Biosciences logo - Similar company to Excellthera

Senti Biosciences

70
C3i logo - Similar company to Excellthera

C3I

89

Top Excellthera Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant